Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: An ink ribbon cartridge includes a first spool, a first case covering the first spool, a second spool, a second case covering the second spool, a first rib provided at the first case, a second rib provided at the second case, an ink ribbon, a first protrusion, and a second protrusion. The first spool extends in a first direction and the second spool extends in a second direction. The first protrusion protrudes in the first direction from an end of the first case in the first direction. The second protrusion protrudes in the second direction from an end of the second case in the second direction. The first protrusion and the second protrusion are respectively fitted in a first hole and a second hole of a first frame of a printing device in a state where the ink ribbon cartridge is attached the printing device.

Abstract: Provided is a liquid crystal display device capable of switching between a transparent state and a scattering state, reducing or preventing a decrease in transmittance in the transparent state, and reducing or preventing a decrease in luminance in the panel central portion in the scattering state. The liquid crystal display device includes, sequentially from its viewing surface side toward its back surface side: a first liquid crystal panel; a light source; and a second liquid crystal panel, the first liquid crystal panel including a polymer dispersed liquid crystal containing a polymer network and liquid crystal components, the light source being configured to irradiate a back surface side main surface of the first liquid crystal panel with light from an oblique direction.

Abstract: A reward providing device comprises an acquiring section that acquires, when charging of the battery by a charging device is completed, battery state-of-charge information concerning a battery state of charge that is a state of charge of a battery provided to a moving body, and a reward providing section that provides a reward to the user of the moving body when the battery state of charge is less than or equal to a recommended upper limit state of charge that is an upper limit of a recommended charge rate set to be lower than a full charge, serving as a state of charge that is recommended.

Abstract: A platinum group metal ion-supported catalyst in which platinum group metal ions or platinum group metal complex ions are supported on a non-particulate organic porous ion exchanger, wherein the non-particulate organic porous ion exchanger is formed of a continuous framework phase and a continuous pore phase; has a thickness of a continuous framework of 1 to 100 ?m, an average diameter of continuous pores of 1 to 1000 ?m, and a total pore volume of 0.5 to 50 ml/g; has an ion exchange capacity per weight in a dry state of 1 to 9 mg equivalent/g; and has ion exchange groups wherein the ion exchange groups are uniformly distributed in the organic porous ion exchanger.

Abstract: A suspension seat, including: a lower side member that forms a vehicle lower side of a suspension; an upper side member that forms a vehicle upper side of the suspension, and that is configured to support a vehicle seat body from the vehicle lower side; a suspension link mechanism that includes a vehicle lower side portion coupled to the lower side member and a vehicle upper side portion coupled to the upper side member, and that undergoes displacement so as to displace the upper side member along a vehicle vertical direction; a linear displacement section that is provided at the suspension link mechanism and is configured to undergo linear displacement in conjunction with displacement of the suspension link mechanism; and a locking mechanism that immobilizes the linear displacement section so as to immobilize displacement of the suspension link mechanism.

Abstract: A waste treatment system, includes: at least one reformer for hydrolyzing waste; a microbial reactor for microbially degrading a reformed material containing at least a solid of the waste hydrolyzed by the at least one reformer; a microbial reaction detection device for detecting a state of degradation of the reformed material in the microbial reactor; and an adjustment device for adjusting amount and timing of supply of the reformed material to the microbial reactor, based on a detected value of the microbial reaction detection device.

Abstract: Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer’s disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6?-(phenyl)-2H-(1,2?-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

Abstract: The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: An attention ability test device includes a display having a display area, an input device for receiving an operation performed by an examinee, and a test controller. While displaying a central image in the central area of the display area and displaying one or more peripheral images in the peripheral area of the display area, the test controller generates at random at least one of a center task of changing the central image and a periphery task of changing the peripheral image, and measures, as a reaction time, the period of time from generation of the center task or the periphery task to execution of a predetermined operation performed by the examinee having recognized the generation, and evaluates the attention ability of the examinee, based on the reaction time.

Abstract: A method for manufacturing a zeolite membrane structure comprises an immersion step for immersing a porous substrate in a synthetic sol, and a synthesis step for hydrothermally synthesizing a zeolite membrane on a surface of the porous substrate that has been immersed in the synthesis so. When the foamability of the synthetic sol is measured by a Ross-Miles method under a condition of 25 degrees C., the foam height after elapse of 5 minutes from completion of down flow is less than or equal to 5 mm.

Abstract: A housing of a scroll type expansion machine includes: a suction port formed at a position on the opposite side to a drive shaft with a fixed scroll interposed therebetween; a discharge port formed on the side of a drive-side bearing closer to the tip end of the drive shaft; a low pressure chamber formed on the outer side of an orbiting-side scroll portion when viewed from the axial direction of the drive shaft; and a tip end-side low-pressure space being a space in which a sealing member is disposed, and has: a partition wall partitioning the tip end-side low-pressure space and the low-pressure chamber from each other; and a communication space communicating the tip end-side low-pressure space with the low-pressure chamber.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Abstract: A method for forming a carbon-carbon bond, wherein a reaction is performed by filling a platinum group metal-supported catalyst into a filling container, and passing a raw material liquid through the platinum group metal-supported catalyst in a continuous circulation manner, and wherein the platinum group metal-supported catalyst is a platinum group metal-supported catalyst in which nanoparticles of a platinum group metal with an average particle diameter of 1 to 100 nm are supported on a non-particulate organic porous ion exchanger formed of a continuous framework phase and a continuous pore phase.

Abstract: A method for recovering an acidic gas, includes: a step of bringing a gas to be treated that contains an acidic gas into gas-liquid into contact with an amine absorbing solution, allowing the amine absorbing solution to absorb the acidic gas, thereby removing the acidic gas from the gas to be treated; a step of allowing the amine absorbing solution that has absorbed the acidic gas to release the acidic gas, thereby regenerating the amine absorbing solution, and at the same time, recovering the released acidic gas; and an analysis step of calculating concentrations of iron ions and/or heavy metal ions in the amine absorbing solution.